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ABSTRACT 28 
 29 
The multiplicity of drug resistant Mycobacterium tuberculosis (Mtb) strains is a growing health 30 
issue. New therapies are needed, acting on new targets. The I3-Ag85 was already reported to 31 
reduce the amount of trehalose dimycolate lipid of the mycobacterial cell wall. This inhibitor 32 
of Ag85c increased the mycobacterial wall permeability. We previously showed that M. 33 
tuberculosis strains, even multi-drug resistant and extensively-drug resistant strains, can be 34 
susceptible to vancomycin when concomitantly treated with a drug altering the cell envelope 35 
integrity. We investigated the effect of the I3-Ag85 on vancomycin susceptibility of M. 36 
tuberculosis. Although no synergy was observed, a new target of this drug was discovered: the 37 
production of phthiodiolone dimycocerosate (PDIM B). 38 
  39 
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The emergence of multi- and extensively drug resistant (MDR and XDR) Mycobacterium 40 
tuberculosis (Mtb) strains emphasized the urgent need for new antitubercular drug development 41 
[1]. In this perspective, we focused on drugs targeting the external lipid envelope of these 42 
bacteria. Mtb, the main causative agent of tuberculosis, has a particular waxy cell wall outward 43 
its peptidoglycan layer. The very long chain fatty acids, up to C100 and called mycolic acids, 44 
are attached to arabinogalactan, which in turn is covalently bound to peptidoglycan. The giant 45 
complex macromolecule interact with extractable waxy lipids, forming a hydrophobic wall [2]. 46 
Among these complex lipids, trehalose dimycolate (TDM), sulfolipids (SL), diacyltrehalose 47 
(DAT), penta- or poly-acyltrehalose (PAT) and phthiocerol- or phthiodiolone dimycocerosate 48 
(PDIM A and PDIM B) are virulence factors important for host interaction. Additionally, both 49 
TDM and PDIM play an important structural role. TDM, known as “cord factor”, is involved 50 
in the host’s immune system modulation during granuloma formation, but it is also involved in 51 
the mycobacteria wall impermeability, conferring protection against drug entrance [3, 4]. PDIM 52 
A and PDIM B have been shown to be involved in mycobacterial wall impermeability against 53 
drugs, oxidative stresses and SDS [5-9]. 54 
The large molecular size of the glycopeptides prevents them from penetrating the waxy Mtb 55 
cell wall. However, in previous articles, we showed that drugs inhibiting PDIM synthesis could 56 
increase the inhibitory action of vancomycin on Mtb [9,10]. The report of Warrier et al., on a 57 
TDM inhibitor specifically targeting the Ag85C on MDR and XDR Mtb clinical strains and 58 
able to improve Mtb permeability to glycerol, raised our attention [11]. The Ag85C is part of 59 
an enzymatic complex including Ag85A and Ag85B, and the most active enzyme involved in 60 
the transfer of mycolic acid residues, carried by trehalose monomycolate (TMM), on 61 
arabinogalactan [12].  62 
Based on Warrier et al. results, we tested the susceptibility of Mtb to vancomycin in the 63 
presence of this inhibitor, I3-Ag85, in order to investigate a potential synergistic effect of this 64 
combination [11]. The I3-Ag85 was synthetized as previously described [13]. We performed 65 
drug susceptibility assay following the agar proportion method on the Mtb H37Rv strain [14]. 66 
Vancomycin and I3-Ag85 were serially diluted alone or in combination in 24-well plates and 67 
inoculated with 10 µl 10-1 to 10-4 dilutions of McFarland No. 1 turbidity culture. The obtained 68 
minimal inhibitory concentration (MIC) were used to calculate the fractional inhibitory 69 
concentration index (FICI) following the Checkerboard method: FICI= MICab/MICa + 70 
MICba/MICb [15]. MICa were 50 µg/ml for vancomycin and MICb was 44 µg/ml for I3-Ag85. 71 
Vancomycin serially diluted with  4.4 µg/ml I3-Ag85 fix concentration still gave an MICab of 72 
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50 µg/ml vancomycin. Similarly, I3-Ag85 serially diluted with 10 µg/ml vancomycin fixed 73 
concentration gave a MICba of 44 µg/ml I3-Ag85. A FICI of  2 was obtained, showing no 74 
synergistic effect of the two drugs.  75 
Since these results suggested that the I3-Ag85 targets, including Ag85C [11], are not involved 76 
in vancomycin resistance, we verified the vancomycin susceptibility by the agar proportion 77 
method of a strain lacking this enzyme (KO), MT0137, obtained by transposon insertion, 78 
compared to the CDC1551 wild type Mtb strain (WT) [16]. The absence of the expression of 79 
the Ag85C in the MT0137 strain was confirmed by proteomic analysis (Fig. S1). In contrast to 80 
the WT strain, no specific peptide corresponding to the Ag85c was identified and sequenced 81 
from the KO sample. The WT and KO strains showed similar MIC for vancomycin (50-200 82 
µg/ml for the WT and 100-200 µg/ml for the KO). Considering that the vancomycin 83 
susceptibility was unchanged in the KO strain compared to WT strain, we considered that 84 
Ag85C is not an interesting target to potentiate glycopeptide effect.  It is worth noting that we 85 
observed the same susceptibility to the I3-Ag85 (22-44 µg/ml) in both strains, as previously 86 
reported by Warrier et al. [11].  87 
I3-Ag85 inhibitory effect should therefore rely on the inhibition of additional targets, including 88 
potentially orthologous Ag85A or B proteins, given that the KO strain is devoid of Ag85C but 89 
shows the same MIC to the inhibitor as the WT strain. We therefore analyzed their lipid 90 
composition by high-pressure thin-layer chromatography (HPTLC) as previously described 91 
[10], comparing midlog-phase growing Mtb CDC1551 WT and KO cultures (with inoculum 92 
size 100 fold higher compared to drug susceptibility assays) , treated or untreated 24 h with  44 93 
µg/ml I3-Ag85 [17]. As described by Warrier et al., we observed a slight decrease of TDM and 94 
an increase of DAT+TMM in the treated WT strain (Fig. 1A and B) [11]. Additionally, we 95 
observed a decrease of acylated phosphatidylinositol hexamannoside (Ac2PIM6) and an 96 
increase of phosphatidyl ethanolamine (PE) (Fig. 1A and B). Although both the I3-Ag85 treated 97 
KO and the WT strains showed an increase of DAT+TMM, the mutant additionally exhibited 98 
a decrease of the triacylglycerol (TAG) and PDIM B (Fig. 1A and C). This decrease of PDIM 99 
B by the I3-Ag85 treatment in  the KO strain is highlighted by the stronger PDIM B HPTLC 100 
signal intensity compared to the untreated WT strain (Fig. 1A). 101 
 As reported by Warrier et al,  mycolic acid methyl esters (MAME) were not notably changed 102 
by the I3-Ag85 treatment, suggesting that other enzymes, including the orthologous Ag85A or 103 
B proteins could rescue mycolic acid transfer on arabinogalactan (data not shown). Considering 104 
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that Warrier et al. also reported a free mycolic acid change, these authors suggested that a 105 
specific effect on the TDM synthesis by this inhibitor [11]. 106 
Our lipid analyses, especially on the KO strain lacking Ag85C, suggest that the I3-Ag85 has an 107 
additional effect by reducing the PDIM B production, either directly or indirectly . Indeed, a 108 
change in the balance between an acetyl-CoA derived lipid (e.g. TMM) and a propionyl-CoA 109 
derived lipids (e.g. PDIM B), as observed by the I3-Ag85 treatment, has been already reported 110 
in a mce1 KO mutant strain [18]. Propionyl-CoA derived lipid synthesis could protect bacteria 111 
against propionate induced toxicity [2]. The inhibition of PDIM synthesis could therefore be 112 
harmful for Mtb and explain the I3-Ag85 susceptibility of both WT and MT0137 fbpC strains.  113 
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FIGURE LEGEND 170 
 171 
Fig. 1. HP-TLC analyses of the CDC1551 wt and ΔfbpC strain lipids. Each experiment was 172 
performed at least three times using independent samples. A. HP-TLC migration profiles of 173 
lipids in petroleum ether/diethyl ether (9 :1) revealed with phosphomolybdic acid to visualise 174 
PDIM (upper panel) or migrated in CHCl3/CH3OH/H2O (60:35:8) revealed with anthrone to 175 
visualise more polar cell wall lipids (lower panel). B. Lipid spots quantification, performed on 176 
HP-TLC using primuline for the revelation, for the wt strain, normalized to the total amount of 177 
lipids in the I3-Ag85 treated condition compared to the DMSO control (set as 100%). C. Lipid 178 
spots quantification, performed on HP-TLC using primuline for the revelation, for the ΔfbpC 179 
strain, normalized to the total amount of lipids in the I3-Ag85 treated condition compared to 180 
the DMSO control.  The relative abundance of the different classes of lipids in B. and C. was 181 
determined by loading 5 μg of lipid mixture onto a HP-TLC silica gel 60 plate (Merck) with a 182 
Camag ATS4 apparatus. The plate was developed in the appropriate solvent mixture using a 183 
Camag ADC2 device and stained by the reagent with a Camag CID3 apparatus, followed by 184 
heating at 150°C for 20 min, when necessary. Lipids were quantified by absorption 185 
measurement at 400 nm with a Camag Scanner 3 device using Wincats software.  186 
 187 
